# TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

> **NCT01170221** · PHASE3 · COMPLETED · sponsor: **Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 667 (actual)

## Conditions studied

- Skin and Subcutaneous Tissue Bacterial Infections

## Interventions

- **DRUG:** TR-701 FA
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT01170221
- **Lead sponsor:** Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-15
- **Primary completion:** 2011-09-30
- **Final completion:** 2011-09-30
- **Target enrollment:** 667 (ACTUAL)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01170221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01170221, "TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01170221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*